Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Bioscience company to manufacture genetic breast cancer risk-assessing reagents
August 4th, 2005
Tm Bioscience Corporation (TMC), a provider of commercial genetic testing products, announced it has signed a 5-year agreement to supply custom Tag-It reagents to InterGenetics, Oklahoma City, Oklahoma, for OncoVue. According to InterGenetics, Oncovue has been developed as the first genetic-based breast cancer risk test relevant to all women. The agreement anticipates InterGenetics will purchase a minimum of $7.5 million in reagents from Tm over the 5-year period. The agreement is contingent on Tm delivering Tag-It reagents which perform according to InterGenetics' specifications. Breast cancer is one of the most frequently diagnosed cancers among...
Source: Women's Health Weekly (2005-08-04)
|
